Global Advanced Research Journal of Medicine and Medical Sciences (GARJMMS) ISSN: 2315-5159
May 2018, Vol. 7(5), pp. 105-110
Copyright © 2018 Global Advanced Research Journals

Full Length Research Article

Comparative analysis of antibacterial potency of six fluoroquinolone antibiotics commonly prescribed in Uyo, Akwa Ibom State, Nigeria in the treatment of Salmonela typhi infections

Akeem Agboke* and Ekanem Etim

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Uyo, Uyo Nigeria.

*Corresponding Author E-mail: ayoagboke@yahoo.com

Accepted 11 August, 2017 

Abstract

Comparative analysis of antimicrobial potency of six common fluoroquinolone antibiotics was done. They were chosen based on their availability and affordability which includes: Ciprofloxacin, Pefloxacin, Levofloxacin, Norfloxacin, Ofloxacin and Sparfloxacin, in the treatment of Salmonela typhi infections in Uyo, Akwa Ibom state of Nigeria. Sensitivity test of different concentrations of the six fluoroquinolones were carried out on the test organism (Salmonella tyhpi) using agar well diffusion method. The Minimum Inhibitory Concentration (MIC) which indicates the strength of each of the fluoroquinolones used on the test organism were determined. The result obtained showed that Pefloxacin had the highest antibacterial strength against the test organism with MIC of 0.0003, followed by Norfloxacin (0.0006), Ciprofloxacin (0.0010), Levofloxacin (0.0016), Ofloxacin (0.0042) and Sparfloxacin having the lowest with MIC of 0.0398. The analysis of variance (ANOVA) showed a significant difference (P<0.05) among the MIC of the six fluoroquinolones used. Post Hoc Test result indicates a significant of 1.000 among the MIC of the six fluoroquinolones.

Keywords: Antimicrobial, Antibiotics, fluoroquinolones and Salmonela typhi

References

Abraham DJ (2003). Quinolone, in Burgerís Medicinal Chemistry Drug Discovery, John

Wiley and Sons, Hoboken, New Jersey. pp. 582-587

Andersson MI, MacGowan AP (2003). "Development of the quinolones". J. Antimicrob. Chemoth. 51 (Suppl. S1): 1–11.

Andrews JM (2001). "Determination of minimum inhibitory concentrations". J. Antimicrob. Chemoth.  48 (suppl 1): 5–16.

Arnold K, Hong CS, Nelwan R, Zavala-Trujillo I, Kadio A, Barros MA, de Garis S (1993). Randomized comparative study of fleroxacin and chloramphenicol in typhoid fever. The Am. J. Med. 94(3A): 195S-200S

Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, Wain J, White NJ, Farrar JJ (2000). A randomised controlled comparison of azithromycin and ofloxacin for multidrug-resistant and nalidixic acid resistant enteric fever. Antimicrobial Agents and Chemotherapy. 44(7):1855-1859.

Cheesbrough M (2006). District Laboratory Practice in Tropical Countries. Cambridge

University Press, p. 434.

Cristiano P, Imparato L, Carpinelli C, Lauria F, Lovene MR, Corrado MF, Maio P, Imperatore C (1995). Pefloxacin versus chloramphenicol in the therapy of typhoid fever. Infection. 23(2): 103-106.

Crump J, Youssef F, Luby SP, Wasfy MO, Rangel JM, Taalat M, Oun SA, Mahoney F (2003). Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emer. Infect. Dis. 9:539–544.

Essential Medicines InDEX (EMDEX), 2014/2015 Edition (Vol. 3). Drug Comparison and Therapeutic details.

Heeb S, Fletcher MP, Chhabra SR, Diggle SP, Williams P, Cámara M (2011). "Quinolones: from antibiotics to autoinducers" (PDF). FEMS Microbiol. Rev. 35 (2): 247–274.

Jolt JG, Krieg NR, Sneath PHA, Stanley JT, Williams ST (1994). Bergey’s manual of systematic bacteriology, 9th edn. Williams & Wilkins Co. Baltimore, Maryland. p786.

Kalra SP, Naithani N, Mehta SR, Swamy AJ (2003). Current Trends in the Management of Typhoid Fever. MJAFI. 59 : 130-135

Naber KG (1991). "The role of quinolones in the treatment of chronic bacterial prostatitis". Infection. 19 Suppl 3: S170–177.

Oyeleke SB, Manga SB (2008). Essentials of Laboratory Practicals in Microbiology Tobest publisher, Minna. Niger, pp. 36-75.

Sharma PC, Jain A, Jain S (2009). Fluoroquinolone antibacterials: a review on chemistry, Microbiology and therapeutic prospects. Acta Poloniae Pharmaceutica ñ Drug Research, 66(6): 587 and 604

Turnidge JD, Ferraro MJ, Jorgensen JH (2003). Susceptibility Test Methods: General Considerations. In PR Murray, EJ Baron, JH Jorgensen, MA Pfaller, RH Yolken. Manual of Clinical Microbiology.8th Ed. Washington. Am. Soc. Clin. Microbiol. p1103

Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL (2015). "Typhoid fever". Lancet, 385 (9973): 1136–1145.

WHO Model List of EssentialMedicines" (PDF). World Health Organization . October 2013. Retrieved 22 April 2014.

WHO Model List of Essential Medicines (April 2015)" (PDF).WHO. April 2015. Retrieved May 10, 2015.

Wispelwey B, Schafer KR (2010). "Fluoroquinolones in the management of community-acquired pneumonia in primary care". Expert. Rev. Anti. Infect. Ther. 8 (11): 1259–1271.